Chair of BioCanRx
Mr. Ken Newport is an entrepreneur and life sciences business executive. As a graduate of the University of Waterloo and a Chartered Accountant, Newport had early success in the financial services industry and served as a partner in a Chartered Accounting firm. His focus changed to life sciences in the mid-nineties with the formation of CroMedica Global Inc., a contract research organization. As co-founder and President he witnessed CroMedica’s growth to 600 employees within six years. By the time that CroMedica merged with PRA International Inc. in 2002, CroMedica had annual revenues of over $40 million with 13 offices in nine countries. The combined company became one of the five largest contract research organizations in the world with 2,600 employees. Mr. Newport served as a Senior Vice President and Executive Committee member until 2005. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is now a corporate director and has earned the ICD.D designation. He serves or has served on several corporate boards including Jennerex, Nordion, MedGenesis, Aeterna Zentaris and many others. In addition, Mr. Newport has volunteered on many boards including serving as Chair of the Ottawa Hospital Research Institute and his current role as Chair of BioCanRx, Canada’s National Centre of Excellence for Immunotherapy Cancer Research.